Another study in the U.K. evaluated adherence to the National Institute for Health and Care Excellence (NICE) guidelines for starting and continuing glucagon-like peptide 1 (GLP1) agonists in patients with T2DM. Here, GLP1R is linked to type 2 diabetes mellitus.